JPM-OEt
Modify Date: 2024-01-05 16:04:05
JPM-OEt structure
|
Common Name | JPM-OEt | ||
|---|---|---|---|---|
| CAS Number | 262381-84-0 | Molecular Weight | 392.44600 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H28N2O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of JPM-OEtJPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity[1][2]. |
| Name | [125I]-JPM-OEt |
|---|---|
| Synonym | More Synonyms |
| Description | JPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | JPM-OEt (50 mg/kg; i.p.; daily for 30 days) reduces tumor cathepsin B activity significantly[1]. JPM-OEt (50 mg/kg; i.p.; twice daily for 4 weeks) leads to tumor regression in the RIP1-Tag2 (RT2) mouse model of pancreatic islet cell tumorigenesis[2]. JPM-OEt (50 mg/kg; i.p.; daily from 63 to 98 days) causes a significant delay in the increase of tumour burden during the first 2 weeks of treatment[3]. Animal Model: Female mice of a transgenic mouse[3] Dosage: 50 mg/kg Administration: i.p.; daily from 63 to 98 days Result: Caused a significant delay in the increase of tumour burden during the first 2 weeks of treatment. However, on days 84, 91 and 98 no significant differences between both groups could be detected. |
| References |
| Molecular Formula | C20H28N2O6 |
|---|---|
| Molecular Weight | 392.44600 |
| Exact Mass | 392.19500 |
| PSA | 117.26000 |
| LogP | 1.69410 |
| Hazard Codes | Xi |
|---|
| JPM-OEt |
| JPMOEt |
| N-[[L-trans-3-(Ethoxycarbonyl)oxiran-2-yl]carbonyl]-L-leucyl-3-(p-hydroxyphenyl)ethylamide |